What is the price of pemetinib targeted drug?

Pemetinib is an innovative targeted therapy designed for adults whose disease has not been controlled by previous treatments. It offers a new treatment option specifically for patients with cholangiocarcinoma that has spread to nearby tissue or other parts of the body and cannot be removed with surgery. Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells. Its onset is insidious and highly invasive. Many patients are already in an advanced stage when diagnosed and lack effective treatments. The emergence of pemetinib has brought new hope to these patients.

The mechanism of action of pemetinib is to inhibit the activity of fibroblast growth factor receptor (FGFR), especially FGFR2, thereby blocking the growth and spread signaling pathways of tumor cells. FGFR plays a key role in the growth and proliferation of various tumor cells such as cholangiocarcinoma, and pemetinib can specifically inhibit this target to achieve anti-tumor effects.

In addition to cholangiocarcinoma, pemetinib is also used to treat a specific blood cancer—myeloid/lymphoid neoplasms (MLN). MLN is a very aggressive tumor, and patients often have no improvement or relapse after other treatments. Through its targeted inhibition mechanism, pemetinib provides a new treatment option for these patients, helping them prolong survival and improve quality of life.

Of course, as a powerful targeted therapy drug, pemetinib may also cause some side effects during use, such as dry eyes, fatigue, nausea, diarrhea, rash, etc. When using pemetinib, patients should strictly follow the doctor's instructions and undergo regular review and monitoring in order to detect and deal with adverse reactions in a timely manner and ensure the safety and effectiveness of the treatment.

Pemetinib has now been launched in the Chinese market, and patients can purchase this drug directly in domestic hospitals. Currently, the original research version of pemetinib is sold in China, with a specification of 4.5 mg and 14 tablets, and the market price is about 30,000 yuan. It is reported that there are two types of original research version and generic version in foreign markets. The price of the original research version with 14 tablets of 13.5mg is about 72,000 yuan, while the generic version produced by Lucius Pharmaceuticals in Laos only costs about 850 yuan with the same specifications. For more consultation on pemetinib, it is recommended to contact regular overseas medical service institutions.

xa0

Reference link: https://medlineplus.gov/druginfo/meds/a620028.html